CNCE stock information

Sector:

Healthcare

Description:

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Concert Pharmaceuticals, Inc. website

Current Price

$8.37

RSI

47.58

Market Capitalization:

247.4M

Beta:

0.488

Volume:

10,733,298

Analyst Target Price:

$ 17.4

Economiic Fair Price:

Earnings DateNovember 08, 2022

Report DateNovember 07, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash95.2M

Debt14.2M

EPS-2.71

Profit MarginN/A

Revenue Per Share TTM0.785

Return On Equity TTM-1.087

YoY Revenue Growth (TTM)

YoY Pre Tax Income Growth (TTM)

-101.99 %

YoY Free Cash Flow (TTM)

-123.24 %

QoQ Revenue Growth

-98.53 %

QoQ Pre Tax Income Growth

-8.34 %

QoQ Free Cash Flow Growth

-39.07 %

2021 Revenue

$ 32.6K

-99.59 %

2020 Revenue

$ 7.9M

633.70 %

2019 Revenue

$ 1.1M

-89.75 %

2018 Revenue

$ 10.5M

-92.70 %

2017 Revenue

$ 143.9M

82595.98 %

2016 Revenue

$ 174K

2021 Free Cash Flow

$ -55.4M

19.98 %

2020 Free Cash Flow

$ -69.2M

-40.05 %

2019 Free Cash Flow

$ -49.4M

2.85 %

2018 Free Cash Flow

$ -50.9M

-149.91 %

2017 Free Cash Flow

$ 102M

321.15 %

2016 Free Cash Flow

$ -46.1M

2021 Pre Tax Income

$ -80.1K

99.89 %

2020 Pre Tax Income

$ -74.9M

4.24 %

2019 Pre Tax Income

$ -78.2M

-40.31 %

2018 Pre Tax Income

$ -55.7M

-158.43 %

2017 Pre Tax Income

$ 95.3M

287.97 %

2016 Pre Tax Income

$ -50.7M

Concert Pharmaceuticals, Inc.(CNCE)